Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
35 results
D2.320 - Safety and tolerability of stepwise oral food challenge using heated whole egg powder: a multicenter study
D2.326 - The frequency of hereditary α-tryptasemia (HαT) in patenits with insect venom anaphylaxis and in patients with mastocytosis – preliminary results
D2.319 - A clinical case of polysensitization and multiple allergies in a 1.5-year-old child
D2.322 - Identifying Risk Factors for Food Allergy and Food-Induced Anaphylaxis Among Korean School-Aged Children: A Nationwide Population-Based Study
D2.323 - Evaluation of Artificial Intelligence Models with Case Scenarios in the Diagnosis and Management of Pediatric Anaphylaxis
D2.324 - Anaphylaxis in very early childhood: An ongoing challenge
D2.325 - Desensitization of Olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency and ochoa syndrome
D2.327 - Patient and caregiver perspectives on sublingual adrenaline for anaphylaxis: findings from an international survey
D2.328 - Pediatric Anaphylaxis in Turkey: Clinical Characteristics, Triggers, and Severity in a Nation-wide Registry
D2.329 - Profilin-mediated anaphylaxis with cofactor
D2.331 - An Adult Case of Cofactor-Induced Anaphylaxis Associated with Physical Exercise
D2.449 - Patients with Inadequately Controlled CRSwNP and Blood Eosinophil Count ≥150 cells/µL Experience Benefit with Depemokimab: An Analysis of Data from the Integrated ANCHOR-1/-2 Studies
D2.447 - Phenotyping of Chronic T2 Inflammatory Diseases of the Nose and Paranasal Sinuses and the Algorithm for Biologic Therapy Selection
D2.448 - Recommendations on Patient Education for Biological Therapy in CRSwNP – An EAACI Position Paper
D2.450 - EUFOREA/EPOS Criteria Applied to a Diverse CRSwNP Cohort: Post Hoc Findings from Twice-Yearly depemokimab ANCHOR-1/-2 trials
D2.451 - Real-life upper and lower airway outcomes of long-term dupilumab treatment in patients with severe chronic rhinosinusitis with nasal polyps
D2.452 - Real-World Trends in the Epidemiology and Burden of Chronic Rhinosinusitis with Nasal Polyps Over Time in Germany Reveal Increasing Prevalence and Low Biologic Use
D2.453 - Olfactory outcomes of dupilumab in patients with CRSwNP: A real-world prospective study
D2.455 - Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD
D2.456 - Chronic sinusitis with nasal polyposis: Add-on aspirin desensitization useful in dupilumab therapy?
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download